Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhealba Oat plantlets extract is a proprietary botanical extract derived from the young shoots (plantlets) of a specific variety of *Avena sativa* (oat), developed by Pierre Fabre (A-Derma). Unlike mature oat grains, the plantlets are harvested at a specific stage of growth to maximize the concentration of active molecules, such as flavonoids and saponins, while being free of detectable proteins to minimize allergic risk. It is primarily used in dermo-cosmetic formulations for its anti-inflammatory, soothing, and skin-repairing properties. It is often formulated into sprays or creams to treat cutaneous pain, irritation, and to promote wound healing following dermatological procedures or minor injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhealba Oat plantlets.